From March 21st to 2018, a number of new 3rd board medical and health companies have become targets for listed companies to compete for mergers and acquisitions. Industry insiders say that medical care is a sunrise industry and the industry is booming. Listed companies acquire new 3rd board medical and health companies. Through business collaboration, it is conducive to promoting industrial integration and upgrading.
Forming business synergy
After receiving IPO counseling for more than one year, the new board enterprise Wolves and Medical were taken by A-share company Weili Medical Center. Weili Medical announced on March 15 that it plans to purchase Wolves and medical stocks by issuing shares and paying cash.
Wolves and Medical Listed New Third Board in April 2016, at medical instruments The segment has a certain response. The main product is a one-time circumcision suturing device. And Veli Medical is mainly engaged in the manufacture of medical plastic products; medical supplies and equipment retail; artificial limbs, artificial organs and implants (in products) manufacturing equipment And so on. Weili Medical and Wolves and Medical can form a certain industrial synergy.
Furui shares intends to purchase approximately 80% of the shares of the company through the issuance of shares. This transaction involves a related party transaction and may result in a change in the control of the listed company.
According to the data, the product of Restech is mainly anti-cholinergic drugs, and the core product is Penehyclidine Hydrochloride Injection (abbreviated as “Toncinine”). It is a new class of drugs in the country. It is used in pre-anesthetic medicine and the respiratory system. disease Clinical fields such as detoxification and drug treatment. The company was founded in 2002 and listed new three boards in January 2015. It delisted from the New Third Board in February of this year. Forrei Co., Ltd. is a company focusing on the field of liver diseases, providing diagnosis of diseases and medical treatment. , The medical service platform company for chronic disease management.
In addition, Zhongzi Capital Management (Beijing) Co., Ltd. ("Zhongli Capital"), the parent company of Jinzi Ham, intends to transfer 10,200,000 shares of Zhongrong Medical, which represents 4.91% of Zhonghe Medical's total share capital, and a total of 7,803 shares are transferred. Ten thousand yuan. Prior to this acquisition, Zhongyi Capital already held a majority stake in Zhongrong Medical. After the transaction was completed, Zhongye Capital’s equity held by Zhongyi Medical increased to 89%. Zhongye Medical focuses on precision medical treatment. , Smart medical, Internet industry, industrial chain integration.
In July 2016, Jinzi ham successively injected Zhongrui Capital with 430 million yuan and 163 million yuan into its controlling shareholder, holding a 51% shareholding ratio and establishing a dual main industry development model.
Have a certain scale
From Weili Medical, the profitability of Furui Shares' proposed acquisition of the target, the annual net profit is more than 10 million yuan.
According to the announcement, the net profits of Force in 2015, 2016 and the first half of 2017 were 26.2953 million yuan, 30.782 million yuan and 12.1966 million yuan respectively. However, the growth rate of net profit decreased year by year to 19.40% and 15.15% respectively. 0.21%.
Wolves and Healthcare's net profit for 2015, 2016 and the first half of 2017 were 15.838 million yuan, 208.894 million yuan and 1721.19 million yuan, respectively, an increase of 682.53%, 31.19%, and 31.10% year-on-year. Despite the decline in net profit growth rate, But still maintain a high growth rate.
In 2016 and in the first half of 2017, Zhongye Medical had a loss of RMB 3.402 million and RMB 7,829,900 respectively. For the main reason for the loss, the company stated that in 2016 and 2017, it gradually acquired the controlling shareholder of Zhongyi Capital. Antik, Chengbo Bio and Chunyu Technology 3 companies, resulting in increased operating costs.
